XML 100 R4.htm IDEA: XBRL DOCUMENT v3.25.4
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Revenues            
Revenues $ 84,246 $ 133,368 $ 361,661 $ 510,626 $ 615,873 $ 731,493
Cost of revenues 2,359 21,505 45,911 71,965 93,296 154,900
Cost of revenues - related party 30,988 29,192 112,839 138,800 142,613 145,092
Gross profit 50,899 82,671 202,911 299,861 379,964 431,501
Operating expenses            
General and administrative expenses 311,379 523,855 3,099,183 2,146,517 3,000,571 3,319,417
Salary and benefits 542,420 242,941 1,797,361 795,255 1,063,781 977,890
Advertising and marketing 104,914 251,330 644,941 1,332,957 1,478,663 2,097,505
Investor relations 33,319 255,000 1,558,319 438,000 453,749 1,100,465
Stock based compensation 6,601,793 567,619 10,767,717 1,881,464 2,355,193 2,155,114
Total operating expenses 7,593,825 1,840,745 17,867,521 6,594,193 8,351,957 9,650,391
Loss from operations (7,542,926) (1,758,074) (17,664,610) (6,294,332) (7,971,993) (9,218,890)
Other (income) expense            
Interest expense 75,850 83,850 13,700
Imputed interest - related party         (6,473)
Interest expense - amortization on discount 241,620 464,298 721,533
Loss from settlement 125,625    
Total other (income) expense 75,850 241,620 209,475 464,298 735,233 (6,473)
Loss before income taxes (7,618,776) (1,999,694) (17,874,085) (6,758,630) (8,707,226) (9,212,417)
Income taxes
Net loss (7,618,776) (1,999,694) (17,874,085) (6,758,630) (8,707,226) (9,212,417)
Net loss attributed to non-controlling interest (558) (461) (658) (837) (1,081)
Net loss attributed to Mangoceuticals, Inc. (7,618,218) (1,999,233) (17,873,427) (6,757,793) $ (8,706,145) $ (9,212,417)
Preferred stock dividend requirements 294,000 294,000 882,000 802,109    
Net loss attributed to Mangoceuticals, Inc. common stockholders $ (7,912,218) $ (2,293,233) $ (18,755,427) $ (7,559,902)    
Basic and diluted loss per share            
Basic loss per share $ (0.69) $ (1.14) $ (2.16) $ (4.28) $ (4.84) $ (8.58)
Diluted loss per share $ (0.69) $ (1.14) $ (2.16) $ (4.28) $ (4.84) $ (8.58)
Weighted average number of shares outstanding            
Basic 11,524,275 2,013,848 8,699,144 1,765,051 1,978,966 [1] 1,074,202 [1]
Diluted 11,524,275 2,013,848 8,699,144 1,765,051 1,978,966 [1] 1,074,202 [1]
[1] Shares and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 15 reverse stock split.